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http:WHAT THIS PAPER ADDS
This study reports the outcome of in situ aortic reconstruction using cryopreserved allografts. It emphasizes the
need for close postoperative surveillance because of the substantial early graft-related complication rate. It
studies the inﬂuence on allograft behavior of two cryopreservation protocols generally reported and used in this
series. It also identiﬁes ﬁve independent predictors of early mortality: age, chronic kidney disease, coronary
disease, prosthetic infection, and urgent procedures.Objectives: To evaluate overall survival and complications of cryopreserved arterial allografts in aortic graft
infections and infected aortic aneurysms.
Methods: A retrospective review of consecutive patients was conducted with native or prosthetic aortic
infections, who underwent local debridement and in situ implantation of a cryopreserved aortic allograft from
September 2004 to June 2012 at the Henri Mondor University Hospital. Patient characteristics, indications for
allograft implantation, perioperative events, bacteriological data, and events related to follow-up were identiﬁed.
The primary outcome was overall survival. Overall survival was estimated using the KaplaneMeier method.
Predictors of postoperative mortality were identiﬁed using uni- and multivariate analysis with a Cox proportional
hazard regression.
Results: During the study period, 54 patients (45 [83%] men, mean age 66.2  10.2 years) underwent aortic
reconstruction using cryopreserved allografts. Indications were native aortic infection in 17 patients and
prosthetic graft infection in 37 patients, including seven aortoenteric ﬁstulae. Twelve aortic reconstructions (22%)
were performed as emergency procedures. The median duration of follow-up was 12.1 months (range 0.4e83.6).
The 30-day mortality rate was 28%. The overall mortality rate was 39% at a median follow-up of 12.1 months.
Early signiﬁcant postoperative complications occurred in 52% of patients. The graft-related mortality rate was 7%.
The graft-related complication rate was 19%. During follow-up, there were two recurrences of aortic infection
and two recurrences of allograft limb occlusion. Multivariate survival analysis identiﬁed age, chronic renal
disease, prosthetic infection, emergent procedure, and coronary disease as independent predictors for
postoperative mortality.
Conclusion: This experience with cryopreserved aortic allografts in aortic reconstructions shows an unsatisfactory
30-day survival rate, as well as a substantial early graft-related complication rate. Longer follow-up is needed in
order to support the preferential use of cryopreserved allografts based on their long-term behavior.
 2014 Published by Elsevier Ltd on behalf of European Society for Vascular Surgery.
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The incidence of infected aortic aneurysms, commonly
referred to as “mycotic aneurysms” is low and reported to
vary from 0.6 to 3.0% of all aneurysms, occurring
throughout the aorta, with 50% in the infrarenal position.1of original article: http://dx.doi.org/10.1016/j.ejvs.2014.05.024
responding author.
il address: pascal.desgranges@gmail.com (P. Desgranges).
-5884/$ e see front matter  2014 Published by Elsevier Ltd on
of European Society for Vascular Surgery.
//dx.doi.org/10.1016/j.ejvs.2014.04.023Vascular graft infection occurs after 0.2e6.0% of in-
terventions.2,3 All surgical options share the same principle:
to perform radical treatment by excising the infected tissues
and material, and to re-establish arterial continuity. Extra-
anatomical reconstruction associated in a simultaneous or
staged manner with in situ debridement has been long
regarded as a reference method. However, in the last
decade, reinfection rates and stump pathology have led to
growing consideration of in situ replacement using different
materials. Cryopreserved arterial allografts offer the ad-
vantages of experimental4,5 and clinical high resistance to
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ity and possible degenerative change.4e6
The aim of this study was to assess the outcome and
complications of patients treated with cryopreserved arte-
rial allografts for aortic graft infections and infected aortic
aneurysms based on a single center experience.
METHODS
A retrospective review of a prospectively maintained data-
base from September 2004 to June 2012 was conducted.
Patients who underwent in situ cryopreserved arterial
allograft implantation for a native or prosthetic aortic
infection at the Henri Mondor University Hospital were
identiﬁed. The patient list was crosschecked using the
database of the tissue bank that provided the allografts.
Diagnosis was based on clinical and biological ﬁndings
combined with computed tomography. Specimens for
microbiological cultures were obtained before surgery (blood
culture and local specimen from infected wounds) and
appropriate antibiotic therapy was prescribed accordingly.
Total removal of the infected graft or aortic tissues was
performed whenever possible. Tissue samples were obtained
for microbiological cultures. The remaining bed was thor-
oughly irrigated with povidone iodine standard solution
diluted in 0.9% isotonic NaCl.Whenever possible, the allograft
was covered with a pedicled anterior omentoplasty. Digestive
ﬁstulae were treated with the help of visceral surgeons.Allograft management
Allografts were harvested frombrain deceasedmultiple organ
donors. Donor serum samples were screened for HIV-1 and
HIV-2 antibodies (p24 antigenemia, HIV RNA polymerase
chain reaction [PCR] test), human T-lymphocyte virus 1 and 2,
hepatitis B virus (RNA PCR test, hepatitis B antigenemia, anti-
HBc antibodies), hepatitis C virus (anti-hepatitis C antibodies,
RNA PCR) and syphilis. Bacteriological controls were per-
formed on the liquid storagemedium.The sterility of the graft
was conﬁrmed by cultures for bacteria and fungi.
After being rinsed with the heparinized saline solution,
the allografts were immersed in the cold (4 C) transfer
medium, which was composed of 0.9% sodium chloride and
0.2% glucose (pH 6.8) without antibiotics. The arterial al-
lografts were stored at 4 C in SCOT solution (Macopharma
Laboratories, Tourcoing, France) containing gentamicin
(50 mg/mL), clindamycin (600 mg/mL), and vancomycin
(500 mg/mL), and cryopreserved within 48e72 hours. They
were transferred into freezing bags (Hemofreeze bag Z2012;
Fresenius HemoCare, L’Arbresue, France). Cryopreservation
solution (100 mL) was added.
Between 1998 and 2002, the cryopreservation solution
was composed of 90 mL of a 4% human serum albumin
solution and 10 mL of dimethyl sulfoxide (DMSO). After 30
minutes of equilibrium at 4 C, the bags were placed in a
controlled rate liquid nitrogen freezing chamber (Planer,
Sunbury-on-Thames, UK) and frozen at a cooling rate
of1 C/minute to 50 C, and 5 C/minute from50 C
to 140 C. The frozen grafts were then stored in the vaporphase of liquid nitrogen until use. On the day of trans-
plantation, frozen arteries were rapidly thawed in a 40 C
water bath. After removal of the cryoprotectant, the graft
was suspended in 100 mL of 0.9% sodium chloride con-
taining 0.2% glucose.
Since 2002, allografts have been permeated for 20minutes
at 4 C in SCOT solution containing 15% DMSO and subse-
quently frozen at 80 C without rate-controlled freezing,
and stored for a maximum of 2 years. At the request of the
vascular surgeon, the bag containing the artery remained at
room temperature in the operating room for exactly 10 mi-
nutes. It was then thawed in prewarmed water (37 C). Af-
terwards, the allografts underwent successive washouts in
heparinized solution at room temperature.The ﬁnal washout
ﬂuid was sampled for bacteriology culture.
Broad-spectrum intravenous antibiotics were adminis-
tered during the operation and the early postoperative
period, and replaced by oral therapy according to the
bacteriological results. Oral antibiotics were administered
for 4e6 weeks.Statistical analysis
A descriptive analysis was performed using mean  SD or
median (interquartile ranges) for continuous variables. For
categorical variables, absolute numbers and percentages
were computed.
Survival analysis. The primary endpoint was the survival
rate, considering two events: death (overall survival) and a
composite event deﬁned as death or the occurrence of a
postoperative complication (event-free survival). The sec-
ondary endpoints were the reintervention rate, the limb
salvage rate, the reinfection rate, and the graft patency rate.
Patient survival rates were determined using the Kaplane
Meier method.
The prognostic signiﬁcance of potential variables was ﬁrst
determined by means of univariate survival analysis (log rank
test): all variables yielding p-values<.20were then integrated
into amultivariate analysis to adjust for possible confounders,
using a Cox proportional hazard regression. The Cox regres-
sion used a backward stepwise selection method with a sig-
niﬁcance criterion set at .05 for inclusion in the model, with
non-signiﬁcant variables being removed at each step of the
selection. The association of each variable with the outcome
was estimated with hazard ratios (HRs) and associated con-
ﬁdence intervals (CIs). Statistical signiﬁcance was assumed at
p < .05; all reported p-values were two-sided.
All statistical analyses were performed with Stata version
11.0 (StataCorp, College Station, TX, USA).RESULTS
Fifty-four patients (45 [83%] men, nine [17%] women; mean
age 66.2  10.2 years) underwent treatment for aortic
infection, including 16 mycotic aneurysms, 37 prosthetic
graft infections, and one infectious aortitis. Twenty-two
(59%) patients with prosthetic infection had the primary
procedure performed at the Henri Mondor University
294 J. Touma et al.Hospital. Overall, 1,520 open and endovascular aortic pro-
cedures were performed during the study period.
The infected segment was the abdominal aorta in 52
cases and thoracic aorta in two.
Of the 37 prosthetic infections, four (11%) involved aortic
stent-grafts, and 33 (89%) occurred on prosthetic grafts.
Among those, seven patients presented with aorto-enteric
ﬁstula.
The mean interval from the aortic graft placement to the
diagnosis of aortic infection was 49.3 months (range 0.34e
324.0 months).
The preoperative characteristics and clinical presentation
of the patients are listed in Table 1.
Allograft reconstruction was performed as an emergency
procedure in 12 patients (22%) because of ruptured mycotic
aneurysm (n ¼ 4); acute bleeding (n ¼ 4), including three
gastrointestinal bleeds through the aorto-enteric ﬁstula;
acute limb ischemia (n ¼ 2); and painful mycotic aneurysm
(n ¼ 2). In two patients presenting with mycotic aneurysm
rupture, initial urgent endovascular exclusion was per-
formed, and then allograft reconstruction was planned. The
remaining 42 patients underwent elective surgery (78%).Operative details
A retroperitoneal approach was used in 17 patients and a
transperitoneal approach was used in 34 patients. ATable 1. Patient characteristics and clinical presentation.
Preoperative characteristics Patients, n (%)
Coronary artery disease/CABG/stenting/
MI >6 months
14 (27)
Congestive heart failure/MI <6 months 3 (6)
Arterial hypertension 38 (72)
COPD 5 (9)
Diabetes mellitus 12 (23)
Hypercholesterolemia 22 (42)
Chronic kidney diseasea 9 (17)
Renal failure under hemoﬁltration 5 (9)
Previous stroke 3 (6)
Smoking 25 (48)
Previous abdominal operation 23 (43)
Clinical presentation
Patients with mycotic aneurysm 17 (31)
Rupture 6 (11)
Abdominal pain 6 (11)
Thoracic pain 2 (4)
Limb ischemia 1 (2)
Infectious syndrome 2 (4)
Patients with infected aortic prosthetic
graft/stent-graft
33 (61)/4 (7)
Infectious syndrome 10 (19)
Groin abscess 19 (35)
Acute limb ischemia 3 (6)
Acute gastroduodenal bleeding 3 (6)
Acute abdominal pain 2 (4)
Aortoenteric ﬁstula 7 (13)
Note. CABG ¼ coronary artery bypass graft; MI ¼ myocardial
infarction; COPD ¼ chronic obstructive pulmonary disease.
a Chronic kidney disease, serum creatinine clearance <60 mL/min.posterolateral thoracotomy was performed in two patients,
and a bilateral subcostal approach in one. Complete
removal of the infected tissues was possible in 89% of pa-
tients. Suprarenal cross-clamping was performed in 21
cases (39%), including eight (15%) supraceliac clamp
localizations.
Allograft reconstruction types were distributed as fol-
lows: aorto-aortic (n ¼ 10), aorto-aortic with visceral and
renal artery reimplantation (n ¼ 4), aorto-bi-iliac (n ¼ 11),
aorto-bifemoral (n ¼ 21), aorto-unifemoral (n ¼ 6), and
aorto-uniiliac (n ¼ 2).
Thirty-three patients (61%) received grafts that had been
preserved at 80 C, while 21 (39%) received grafts that
were treated and preserved at 150 C according to the
classic protocol.
Bacteriological cultures of intraoperative samples were
positive in 33 patients. The incriminating microorganisms
are shown in Table 2.
Intraoperative complications and their management are
reported in Table 3.The early postoperative course
The early mortality rate (i.e., prior to day 30) was 28%. Two
patients had suffered from native aortic infection. The 13
other early dying patients were from the group who had
prosthetic graft infection (10 prosthetic grafts, three stent-
grafts), including four patients with aortoenteric ﬁstulae.
Causes of early mortality were acute bleeding in four
patients (one digestive bleeding, two anastomotic disrup-
tions, one intraoperative bleeding), multi-organ failure in
four (including three ischemic colitis), acute respiratory
distress syndrome in two, septic shock in two, and cardiac
failure and pulmonary embolism in one patient each. One
patient died suddenly after transfer to the referring hospi-
tal, without clear etiology.
Signiﬁcant early postoperative complications occurred in
28 (52%) patients (Table 4). In 10 (19%) patients theTable 2. Microorganisms from intraoperative sample culture.
Polymicrobial intestinal spectrum bacteria (n ¼ 6) are excluded.
Microorganism n (%)
Staphylococcus aureus 13 (3 MRSA) (39.4)
Escherichia coli 4 (12.1)
Pseudomonas aeruginosa 3 (9)
Candida albicans 2 (6)
Coagulase-negative Staphylococcus 2 (6)
Campylobacter jejuni 1 (3)
Group B Streptococcus 1 (3)
Staphylococcus warneri 1 (3)
Klebsiella pneumoniae 1 (3)
Citrobacter koseri 1 (3)
Serratia marcescens 1 (3)
Clostridium septicum 1 (3)
Proteus mirabilis 1 (3)
Enterococcus fecalis 1 (3)
Acinetobacter baumanni 1 (3)
Klebsiella oxytoca 1 (3)
Note. MRSA ¼ methicillin-resistant Staphylococcus aureus.
Table 3. Management and outcome of intraoperative complications.
Intraoperative
complications
n (%) Intraoperative
management
Immediate
outcome
Early and mid-term
follow-up
Vena cava/iliac vein wound 3 (5.5) Direct suture Successful One redo at day 5 for
hemostasis
Infrainguinal thrombosis 3 (5.5) Thrombectomy þ in
situ ﬁbrinolysis
Successful Patent vessels
One infection recurrence
(on pre-existing bypass)
Allograft leg/anastomotic
occlusion
3 (5.5) Thrombectomy (n ¼ 2)
Stenting (n ¼ 1)
Successful Patent vessel
Intestinal erosion 1 (1.8) Direct suture of
serous membrane
Successful No complication
Ureteral wound 1 (1.8) Double J catheter Successful No complication
Acute bleeding 1 (1.8) Hemostatic maneuvres Failure Intraoperative death/
acute myocardial infarct
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motic disruptions, four allograft body disruptions, three
allograft leg/branch thromboses and one allograft leg
dissection). Four of these patients died from causes directly
related to the graft, bringing the graft-related mortality rate
to 7%. Nineteen (35%) patients required 34 urgent reopera-
tions: seven intestinal resections, 14 hemostasis maneuvers,
10 revascularization procedures, one nephrectomy, one vena
cava thrombectomy, and one thoracic endograft placement.
One amputation was performed during the ﬁrst post-
operative month, and none during the follow-up period.
Thus, the limb salvage rate was 97%.Early and late graft patency rate
There were six early allograft occlusions, always occurring
on branches (iliac limbs, renal bypass).Table 4. Early postoperative complications (prior to day 30).
Early postoperative complications Patients, n (%)
Acute bleeding 11 (20)
Hemorrhagic shock 6
Retroperitoneal bleeding necessitating
revision surgery
4
Anastomotic/allograft disruption 6
Anastomotic pseudoaneurysm 1
Ischemic events 13 (24)
Ischemic colitis with bowel resection 6
Lower limb by allograft segmental
occlusion
4
Non-graft related lower limb ischemia 2
Renal ischemia by allograft bypass
thrombosis
1
Cardiac events 4 (7)
Acute coronary syndrome 3
Arrhythmia 1
Pulmonary events 8 (15)
Acute respiratory failure 6
Pulmonary embolism 2
Deep vein thrombosis 2
Acute renal failure 3
Paraplegia 1
Persistent infection 3
Multi-organ failure 3Among the patients who survived the early postoperative
period, two (5%) suffered from allograft branch occlusion
leading to additional bypass at 6 months in one case, and
medical management in the second case.
Reinfection rate
Two patients developed obvious signs of reinfection at days
45 and 63 respectively. Both presented with aortic pseu-
doaneurysm around the proximal anastomosis with signs of
systemic infection. The ﬁrst patient died from acute respi-
ratory distress syndrome before reoperation could be per-
formed. The second patient had an aortoenteric ﬁstula. The
reintervention consisted of an extra-anatomic bypass, but
the patient died from severe coagulation disorders.
Late outcomes
Three patients died at days 33, 45, and 70, respectively,
before discharge, bringing the in-hospital mortality rate to
33%.
Three patients died during the follow-up period, after
discharge, in postoperative months 2, 10, and 33, respec-
tively. The ﬁrst death was related to treatment, with an
outbreakof new aortic pseudoaneurysm, as described above.
The two remaining deaths were not related to treatment.
The overall mortality rate in the mycotic aneurysm group
was 18%, while it reached 49% in the prosthetic infection
group, including the seven patients who presentedwith aorto-
enteric ﬁstulae, ﬁve of whom died during hospitalization.
No late degenerative change of the allograft was
observed during follow-up.
Survival analysis
The median follow-up period for surviving patients was 12.1
months (range 0.4e83.6 months). The mean follow-up was
19.8 months. The overall mortality rate was 39% (21 of 54
patients). The rate of mortality or postoperative complica-
tions over the study period was 55% (31 patients), with a
median overall and complication-free survival of 1.5 months
(95% CI 0.9e9.4).
KaplaneMeier survival curves for overall survival and
event-free survival are shown in Fig. 1.
Figure 1. KaplaneMeier survival estimate. (A) Overall survival. (B) Overall and complication-free survival. Note. CI ¼ conﬁdence interval.
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Univariate analysis identiﬁed eight factors signiﬁcantly
associated with postoperative mortality: age >65 years,
arterial hypertension, coronary disease, chronic renal
insufﬁciency, urgent procedures, early revision surgery,
prosthetic infection, and the presence of aorto-enteric
ﬁstulae (Table 5). Multivariate analysis demonstrated that
age (HR 4.4, 95% CI 1.8e10.8), chronic renal disease (HR
10.9, 95% CI 2.4e48.9), prosthetic infection (HR 6.6, 95% CI
1.3e32.7), urgent procedures (HR 5.2, 95% CI 1.2e23.3),
and coronary disease (HR 3.9, 95% CI 1.0e14.5) were
independently related to mortality. Early revision surgery
was not entered into the multivariate analysis, being anTable 5. Clinical factors associated with all-causes death and with post
survival analysis.
Clinical factors Overall,
n ¼ 54
patients (%)a
Event: all-causes death
Unadjusted HR
(95% CI)
pb A
(
Age (years) 66.2 (10.2) 3.6 (1.7e7.4)e .00 4
Sex (male) 45 (83) 1.1 (0.3e5.0) .88
High blood pressure 38 (72) 5.4 (0.7e41.4) .07
Dyslipidemia 22 (42) 0.8 (0.3e2.4) .68
Diabetes 12 (23) 0.5 (0.1e2.3) .36
Smoking 25 (48) 0.6 (0.2e1.8) .35
Coronary disease 14 (27) 2.2 (0.8e6.3) .14
Chronic kidney disease 9 (17) 2.7 (0.9e8.0) .07 1
Emergency treatment 11 (21) 2.4 (0.8e7.2) .11
Prosthesis or endoprosthesis
infection
37 (69) 3.4 (0.8e15.4) .11
Aorto-enteric ﬁstulae 7 (14) 3.7 (1.0e14.1) .04
Suprarenal aortic clamping 20 (38) 1.4 (0.5e3.9) .57
Graft age (mo)d 6 (3; 15) 1.0 (0.98e1.03) .50
Cryopreservation
protocol: 80 C
33 (61) 1.4 (0.4e4.9) .65
Operating time (h) 5 (4; 7) 0.9 (0.6e1.3) .49
Early revision surgery 10 (19) 4.2 (1.4e12.5) .01
a n (%), mean (SD) or
median (Q1; Q3).
b Log rank test.
c Cox regression.
d Time from preservation to implantation.
e Per 10 years.intermediate factor between the initial intervention and the
outcome. Furthermore, when all predictors are present, the
30-day survival rate would fall to 0%. When combining the
most frequently encountered predictors according to our
patients’ characteristics, a 65-year-old man with coronary
disease and elective reconstruction of prosthetic infection
had a predicted 30-day survival rate of 88%.
Prognostic factors for postoperative complication or
mortality (event-free survival)
Univariate analysis identiﬁed ﬁve factors associated with
mortality or postoperative complication: age, diabetes,
chronic kidney disease, early revision surgery, and, age ofoperative complications or all-causes death: overall and event-free
Event: postoperative complications or all-
causes death
djusted HR
95% CI)
pc Unadjusted HR
(95% CI)
pb Adjusted HR
(95% CI)
pc
.4e (1.8e10.8) .00 2.4e (1.5e4.0) .00 2.8e (1.6e4.9) .00
0.8 (0.3e2.4) .68
2.0 (0.7e5.8) .22
0.7 (0.3e1.6) .36
0.4 (0.1e1.5) .16
0.8 (0.3e1.9) .61
3.9 (1.0e14.5) .04 1.3 (0.5e3.1) .59
0.9 (2.4e48.9) .00 2.0 (0.7e5.1) .17 3.4 (1.2e9.6) .02
5.2 (1.2e23.3) .03 1.5 (0.6e3.7) .44
6.6 (1.3e32.7) .02 1.4 (0.6e3.5) .43
2.0 (0.6e6.9) .28
1.7 (0.7e3.8) .23
1.0 (1.00e1.03) .05
1.1 (0.4e3.3) .87
0.9 (0.6e1.2) .42
3.7 (1.6e8.6) .00
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1.6e4.9) and chronic kidney disease (HR 3.4, 95% CI 1.2e
9.6), as independent predictors of postoperative death or
complication.
Neither allograft age nor cryopreservation protocol were
independent prognostic factors in the multivariate analysis.
The presence of an aortoenteric ﬁstula appears to be
correlated with early death only in univariate analysis
(p ¼ .04). In particular, stent-graft infection was not
correlated with a negative outcome (p ¼ .23). The rela-
tionship between cryopreservation protocol and the
occurrence of graft-related complications was tested: two
(18%) patients who received the 150 C protocol and six
(18%) patients who received the 80 C protocol devel-
oped a graft-related complication. The difference was not
signiﬁcant (Fisher’s test p-value ¼ 1.0).DISCUSSION
Many therapeutic options address aortic infections. On ac-
count of considerable early mortality (up to 27%7,8) and
issues such as bypass infection (8e27%7e9), and aortic
stump or prosthetic rupture (9e15%), extra-anatomical
bypass is no longer considered the treatment of choice.
Any alternative technique, especially in situ reconstruction,
is supposed to achieve a better mortality, patency, and
reinfection rate.
The expected beneﬁts of cryopreserved allografts are
numerous: better applicability than autologous tissues,
shortening of the duration and magnitude of the inter-
vention when harvesting veins, and a reduction in the
reinfection rate. This study highlights the following:
 a high early mortality and graft-related complication
rate;
 the signiﬁcant predictive value of age, impaired renal
function, coronary disease, urgent procedure, and
prosthetic infections;
 the equivalent early behavior of allografts, whether
preserved at 80 C or after controlled-rate freezing
at 150 C, independently of the graft age.Mortality
In this series, early postoperative mortality reaches 28%.
This value is greater than reported in series published
during the last decade where mortality ranges from 18% to
22%;6,9e11 in the experience of Bisdas et al., it even falls to
9%.12 The characteristics of the patients in this study are
comparable with those included in the other studies dis-
cussed. In this study, the suprarenal clamping rate reached
39%, which is comparable with the series of Kieffer et al.
(38%),6 without it being a signiﬁcant risk factor of mortality.
The bacteriological data obtained in this study are close to
the spectrum generally reported, with a predominance of
Staphylococcus aureus (34.4%). When this series is
compared with the study reported by Bisdas et al.,12 which
had a similar number and type of patients, and asigniﬁcantly lower early mortality rate, a few differences
should be highlighted: homografts were stored in the vapor
phase of liquid nitrogen and were impregnated with
neomycin, and only 20% of mycotic aneurysms were
ruptured at presentation.
A previous study, performed when the regular use of
cryopreserved arterial allografts began, reported a 30-day
mortality rate of 22%.
Early and late graft-related complications
In 10 patients (19%), early complications were related to
the graft (rupture, thrombosis, dissection). Non-
anastomotic mid-graft rupture occurred in four patients
with high-risk infections (two aorto-enteric ﬁstulae, two
infections with Gram-negative bacteria) and were seemingly
related to a local virulent infectious process. That cryo-
preservation induces allograft fragility is another hypothe-
sis. In the series by Noel et al.,10 26% of patients had
allograft-related early complications. This rate falls to 7%
and even 0% in other series.12,13 Among the 179 patients
reported by Kieffer et al.,6 36 underwent 42 (20%) revisions,
of which eight (19%) were related to the use of allografts,
the majority being fresh allografts. The high rate of early
graft-related complications seen in the study appears to be
the main impediment to the utilization of cryopreserved
allografts. The historical impediment to the use of allografts
has been the late degenerative change and is actually cur-
bed by the abandonment of the use of fresh allografts and
the avoidance of thoracic segments, both of which are
prognostic factors for late events.6 Such lesions can
generally be addressed by minimally invasive endovascular
procedures.14 Their rate of occurrence is low, ranging from
0% to 10%,9,12e14 but caution is still required because
longer follow-up is needed. In this report there were two
graft occlusions and no graft dilations.
Alternative reconstruction material
During the study period, the policy was to perform sys-
tematic in situ allograft replacement, the tissue bank being
part of the Henri Mondor University Hospital. Thus, there
were few reconstructions using alternative materials or
ﬁrst-intention extra-anatomical bypass.
In the series of Batt et al.,15 silver-coated graft usage is
associated with a perioperative mortality of 17%, while it
decreased to 7% among the 27 patients studied by Pupka
et al.16 In both reports, the number of revision procedures
is not explicit.
As for rifampicin-soaked grafts, Oderich et al.7 reported
an early mortality rate of only 8%, without further mention
of the reintervention rate. Ehsan and Gibbons,17 who used
autologous veins, report a mortality rate of 5% for aortic
reconstructions (n ¼ 16) and extra-aortic reconstructions.
However, venous reconstruction is unsuitable for the
emergent situation.18 Interestingly, O’Connor et al.19
calculated the combined mean rate of adverse events
(mortality, amputation, reinfection). The event rate was
0.16 for extra-anatomical bypass, 0.07 for rifampicin-coated
298 J. Touma et al.prosthesis, 0.09 for cryopreserved allografts, and 0.10 for
veins.19
Cryopreservation method
Two cryopreservation protocols (80 C and 150 C) were
used. All allografts that had been cryopreserved at 150 C
were either harvested before 2002 or imported from other
tissue banks that used this protocol, with no expiration
date. Starting from 2002, all grafts preserved at the tissue
bank of the Henri Mondor University Hospital were stored
at 80 C. The use of a 80 C freezing protocol was
supported by the occurrence of allograft fractures after
cryopreservation using nitrogen vapor at 150 C20e22 and
lesions of extracellular matrix during manipulations in cold
nitrogen.23 In addition, graft preservation at 80 C resul-
ted in no difference in the structural or mechanical prop-
erties of rabbit carotids.24 In clinical terms, Castier et al.25
used human allografts preserved at 80 C in peripheral
reconstructions, and did not report any allograft thrombosis
or disruption with a mean follow-up of 34 months. In the
series 61% of patients received grafts that had been cry-
opreserved at 80 C. The cryopreservation protocol did
not have a signiﬁcant inﬂuence on early mortality (p ¼ .76)
or postoperative complication rate (p ¼ .87) The relation-
ship between cryopreservation method and the occurrence
of graft rupture or thrombosis was tested, and no difference
was found between the protocols. This relationship could
not be reliably assessed, as the study of factors associated
with graft-related complications was affected by the fact
that early mortality might have prevented the detection of
these complications. Knowing that grafts preserved
at 80 C were meant to be used within 2 years, we
studied the duration of cryopreservation and found that
grafts stored at 80 C were most frequently used within 6
months, as median graft age at use was 4.7 months; how-
ever, it was 18.5 months for the allografts kept at 150 C.
After performing statistical analysis, the age of allograft was
found to be a predictive factor in the univariate analysis for
the occurrence of death or postoperative complications.
CONCLUSION
Unsatisfactory results for the use of cryopreserved allo-
grafts during in situ reconstruction of infected aortic an-
eurysms or grafts were observed. These results are difﬁcult
to interpret when compared with other series of similar
populations and clinical and procedural data. The main
obstacle appears to be the rate of early graft-related com-
plications. The reinfection and limb salvage rates were
satisfactory. Age, chronic renal disease, coronary disease,
prosthetic infections, and urgent procedures were inde-
pendent prognostic factors for postoperative mortality.
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